An observational study in Tuberculosis, sponsored by Research Center Borstel. Recruiting at 1 site in Romania. Open to participants aged 0 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Research Center Borstel · Observational
This study aims at identifying and evaluating novel diagnostic methods for children evaluated for respiratory tuberculosis. The investigators will use alternative samples like stool, urine, and masks to diagnose children with respiratory tuberculosis. Once diagnosed, the investigators will use target next generation sequencing to determine if the bacillus is resistant to any of the drugs used for treatment. Additionally, children initiated under TB treatment will be followed-up during treatment to measure blood biomarkers for outcome prediction. Finally, spirometry will be performed longitudinally until 3 months after the end of treatment to assess the lung capacity of children treated for respiratory TB. All children initiated on TB treatment will fill in a quality of life questionnaire.
Tuberculosis (TB) remains a significant global health concern, particularly among children, who are especially vulnerable, with an estimated 1.25 million incident cases and 214,000 deaths reported in 2022. TB in children presents unique challenges due to its subtle clinical manifestations and paucibacillary nature, often resulting in difficulties in diagnosis. Compared to estimated incidence, only 49% children were diagnosed and reported, with the highest proportion of under-reporting taking place in children under 5 years - of 58%. Gaps and challenges persist in accurately diagnosing and treating TB in children, stemming from limitations in traditional diagnostic methods, like sputum culture, that often lack sensitivity and specificity in children. Therefore, there is a pressing need to identify new diagnostic techniques that are both accurate and feasible in pediatric settings.
In recent years, researchers have explored innovative approaches, including the utilization of alternative sample types such as mask samples, urine, or stool, for TB diagnosis in children. These alternative samples offer potential advantages in terms of ease of collection and potentially improved diagnostic accuracy. In 2021, the World Health Organization (WHO) recommended stool as an alternative sample for TB diagnosis in children with signs and symptoms of TB, since stool is non-invasive and easy to collect even in young children. A recent systematic review showed that Xpert Ultra summary sensitivity verified by culture was 56.1% (95% CI 39.1 to 71.7), and specificity was 98.0% (95% CI 93.3 to 99.4), nevertheless the sensitivity results are highlighted as "moderate quality evidence", therefore more research is needed on the performance of this alternative sample in children for the diagnosis of tuberculosis. Moreover, the lipoarabinomannan (LAM) found in the membrane of the Mycobacterium tuberculosis bacillus can be identified in urine and pilot data generated by our group shows a sensitivity of 66% in adults with culture-confirmed pulmonary tuberculosis. This urine-based assay can be critically useful in the diagnosis of extrapulmonary TB as it's not sputum-based. In addition to stool and urine, another promising sample can be obtained through a gelatin strip inside a mask worn by children with presumptive TB. The exhaled breath potentially containing M. tuberculosis bacilli is then captured on the gelatin filter, processed, and tested using GeneXpert.
Once the tuberculosis diagnosis is made, an important challenge lies in drug susceptibility testing (DST), in case of multi-drug resistant TB or rifampicin-resistant TB (MDR/RR-TB)(6). The standard of care for DST is sputum culture, which has many challenges in children, as highlighted above. Targeted next-generation sequencing (tNGS) has emerged as a promising tool for assessing drug sensitivity, providing valuable insights into personalized treatment regimens for pediatric TB cases. In addition, tNGS can be performed on clinical samples like sputum or stool with the potential of a rapidly-available result informing the choice of regimen and clinical decision-making.
After treatment initiation, a main concern lies in treatment monitoring, this step being especially challenging in children. Transcriptomics holds promise for monitoring treatment response in children with TB. By examining gene expression patterns, transcriptomic analyses can offer valuable insights into the efficacy of treatment regimens and help identify early indicators of treatment failure or relapse. Both WHO definitions and TBnet definitions will be used to assess TB outcomes.
Understanding and assessing the burden of post-TB sequelae in children is crucial for ensuring comprehensive care and addressing long-term health outcomes. Therefore, studying and evaluating port-TB disease in children is imperative for improving clinical management strategies and enhancing the overall health outcomes of pediatric TB patients. Spirometry will be used to assess pulmonary function in children.
This study aims to research a novel and comprehensive approach to TB diagnosis, treatment adaptation, and treatment monitoring in the pediatric population, with the overall goal of improving TB outcomes in children.
Aims and objectives
Aim: Improve the diagnosis of tuberculosis and treatment outcomes in children evaluated for tuberculosis
Specific objectives:
1,417 studies on the registry are indexed under Tuberculosis; 208 are open to participants now.
This study's planned enrollment of 100 is below the median of 250 across 421 observational studies indexed under Tuberculosis.
Browse Tuberculosis studies →Research Center Borstel is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All potential participants presenting with the inclusion criteria, will be asked to participate in the study upon their parent/guardian consent and their assent, if applicable. Information will be provided about the study and the risks and benefits of participating. Both the child and the parent/guardian are then asked to consent (or assent) to the participation in the study and any questions they might have are answered. The enrollment is complete after the signature of the informed consent form (ICF). If the child or their parent/guardian does not wish to participate in the study, they will receive the standard of care.
Exclusion criteria
Stool diagnostic accuracy
Evaluate the diagnostic accuracy of stool and perform targeted next generation sequencing from stool for drug sensitivity testing.
Time frame: at baseline
Biomarkers for treatment monitoring
Assess the utility of a transcriptomic signature composed of a 22-gene RNA model (TB22 - PMID: 33574078) for treatment monitoring and treatment shortening in children treated for respiratory tuberculosis.
Time frame: from baseline to 9 months pos-enrollment (6 months of treatment + 3 months follow-up post-treatment)
Masks diagnostic accuracy
Identify the diagnostic accuracy of mask strip samples against a composite reference standard for the diagnosis of respiratory tuberculosis in children.
Time frame: baseline
Urinary LAM diagnostic accuracy
Determine the diagnostic accuracy of a novel urinary LAM assay against a composite reference standard for the diagnosis of respiratory tuberculosis in children.
Time frame: baseline
Post-TB lung disease assessment
Measure the forced vital capacity as a marker of lung function in children diagnosed with respiratory tuberculosis using spirometry.
Time frame: from baseline to 9 months post-enrollment (6 months of treatment + 3 months follow-up post-treatment)
Quality of life assessment
Assess the quality of life of children treated for respiratory tuberculosis at baseline, during, and after treatment, using the validated PedsQL questionnaire translated into Romanian and adapted to each age (only the parents respond to the questionnaire for 1-12 months, or 13-24 months; both children and parents respond to the questionnaire for 2-4, or 5-7, or 8-12, or 13-15 years). Higher scores translate to a poorer quality of life.
Time frame: from baseline to 9 months post-enrollment (6 months of treatment + 3 months follow-up post-treatment)
Plan to share: Yes — IPD can be shared upon specific request from the study sponsor and after a written agreement is signed
Supporting information: Study protocol, Icf
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Research Center Borstel